1887

Abstract

The protective-antigen (PA)-based cell-free vaccine is the only vaccine licensed for use against infection in humans. Although the PA shows strong immunogenicity, the capsule or spore-associated somatic antigens may be important as additional vaccine targets for full protection against anthrax. In this study, the protective effect of spore-associated antigens against infection was determined. Rabbits were immunized with formalin-fixed spores of a non-toxigenic unencapsulated strain that lacked the two virulence plasmids pXO1 and pXO2, and the protective effects of the immune antibody were evaluated. Immunostaining and Western blot analysis revealed that the anti- (anti-BA)-spore IgG specifically bound to the surface of spores or endospores of , but not to vegetative cells, or closely related species, such as , and . Passively transferred anti-BA-spore IgG protected mice from intraperitoneal challenge with a lethal dose of fully virulent spores, and increased the survival rate in a dose-dependent manner. Pre-incubation of spores with antibody also reduced their infectivity in a dose-dependent manner. The number of bacteria (c.f.u.) in spleens and livers of infected mice was significantly lower in antibody-treated mice than in untreated mice. Treatment with anti-BA-spore IgG also inhibited the germination of spores in J774.1 macrophages, suggesting that opsonization of spores promotes phagocytosis and subsequent killing by macrophages. These results indicate the usefulness of spore surface antigens as vaccine targets. In combination with major virulence factors such as the PA, spore-associated antigens may offer a safer and more effective multicomponent vaccine for infection.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.28788-0
2006-10-01
2020-07-13
Loading full text...

Full text loading...

/deliver/fulltext/micro/152/10/3103.html?itemId=/content/journal/micro/10.1099/mic.0.28788-0&mimeType=html&fmt=ahah

References

  1. Beedham R. J, Turnbull P. C, Williamson E. D. 2001; Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine19:4409–4416[CrossRef]
    [Google Scholar]
  2. Brey R. N. 2005; Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev57:1266–1292[CrossRef]
    [Google Scholar]
  3. Brossier F, Levy M, Mock M. 2002; Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun70:661–664
    [Google Scholar]
  4. Cohen S, Mendelson I, Altboum Z.12 other authors 2000; Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun68:4549–4558[CrossRef]
    [Google Scholar]
  5. Dixon T. C, Fadl A. A, Koehler T. M, Swanson J. A, Hanna P. C. 2000; Early Bacillus anthracis –macrophage interactions: intracellular survival and escape. Cell Microbiol2:453–463[CrossRef]
    [Google Scholar]
  6. Gu M. L, Leppla S. H, Klinman D. M. 1999; Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine17:340–344[CrossRef]
    [Google Scholar]
  7. Guidi-Rontani C, Weber-Levy M, Labruyere E, Mock M. 1999; Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol31:9–17[CrossRef]
    [Google Scholar]
  8. Guidi-Rontani C, Levy M, Ohayon H, Mock M. 2001; Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol42:931–938[CrossRef]
    [Google Scholar]
  9. Hahn U. K, Boehm R, Beyer W. 2005; DNA vaccination against anthrax in mice – combination of anti-spore and anti-toxin components. Vaccine24:4569–4571
    [Google Scholar]
  10. Huang C. M, Foster K. W, DeSilva T. S, Van Kampen K. R, Elmets C. A, Tang D. C. 2004; Identification of Bacillus anthracis proteins associated with germination and early outgrowth by proteomic profiling of anthrax spores. Proteomics4:2653–2661[CrossRef]
    [Google Scholar]
  11. Iacono-Connors L. C, Welkos S. L, Ivins B. E, Drarymple J. M. 1991; Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun59:1961–1965
    [Google Scholar]
  12. Inglesby T. V, O'Toole T, Henderson D. A. 14 authors 2002; Anthrax as biological weapon. JAMA287:2236–2252[CrossRef]
    [Google Scholar]
  13. Jernigan J. A, Stephens D. S, Ashford D. A.20 other authors 2001; Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis7:933–944[CrossRef]
    [Google Scholar]
  14. Jernigan D. B, Raghunathan P. L, Bell B. P.32 other authors 2002; Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis8:1019–1028[CrossRef]
    [Google Scholar]
  15. Joyce J, Cook J, Chabot D.11 other authors 2006; Immunogenicity and protective efficacy of Bacillus anthracis poly- γ -d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem281:4831–4843[CrossRef]
    [Google Scholar]
  16. Kim H. S, Sherman D, Johnson F, Aronson A. I. 2004; Characterization of a major Bacillus anthracis spore coat protein and its role in spore inactivation. J Bacteriol186:2413–2417[CrossRef]
    [Google Scholar]
  17. Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z. 2002; Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun70:544–560[CrossRef]
    [Google Scholar]
  18. Kudva I. T, Griffin R. W, Garren J. M, Calderwood S. B, John M. 2005; Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect Immun73:5685–5696[CrossRef]
    [Google Scholar]
  19. Little S. F, Knudson G. B. 1986; Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun52:509–512
    [Google Scholar]
  20. Makino S, Sasakawa S, Uchida I, Terakado N, Yoshikawa M. 1988; Cloning and CO[sub]2[/sub]-dependent expression of the genetic region for encapsulation from Bacillus anthracis . Mol Microbiol2:371–376[CrossRef]
    [Google Scholar]
  21. Mendelson I, Gat O, Aloni-Grinstein R.7 other authors 2005; Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine23:5688–5697[CrossRef]
    [Google Scholar]
  22. Mikesell P. B, Ivins B. E, Ristroph J. D, Dreier T. M. 1983; Evidence for plasmid-mediated toxin production in Bacillus anthracis . Infect Immun39:371–376
    [Google Scholar]
  23. Mock M, Fouet A. 2001; Anthrax. Annu Rev Microbiol55:647–671[CrossRef]
    [Google Scholar]
  24. Nourez M, Lacy D. B, Cunningham K, Legmann R, Sellman B. R, Mogridge J, Collier R. J. 2002; 2001: a year of major advances in anthrax toxin research. Trends Microbiol10:287–293[CrossRef]
    [Google Scholar]
  25. Okinaka R. T, Cloud K, Hampton O.11 other authors 1999a; Sequence, assembly and analysis of pXO1 and pXO2. J Appl Microbiol87:261–262[CrossRef]
    [Google Scholar]
  26. Okinaka R. T, Cloud K, Hampton O.12 other authors 1999b; Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol181:6509–6515
    [Google Scholar]
  27. Pitt M. L, Little S. F, Ivins B. E, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander A. M. 2001; In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine19:4768–4773[CrossRef]
    [Google Scholar]
  28. Ramirez D. M, Leppla S. H, Schneerson R, Shiloach J. 2002; Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis . J Ind Microbiol Biotechnol28:232–238[CrossRef]
    [Google Scholar]
  29. Read T. D, Salzberg S. L, Pop M.10 other authors 2002; Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis . Science296:2028–2033[CrossRef]
    [Google Scholar]
  30. Rhie G. E, Park Y. M, Chun J. H, Yoo C. K, Seong W. K, Oh H. B. 2005; Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis . FEMS Immunol Med Microbiol45:331–339[CrossRef]
    [Google Scholar]
  31. Romanov G. I. 1980; Preparation, control and application of anthrax vaccine in USSR. Arch Exp Veterinarmed34:119–122 in German
    [Google Scholar]
  32. Steichen C, Chen P, Kearney J. F, Turnbough C. L. Jr. 2003; Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J Bacteriol185:1903–1910[CrossRef]
    [Google Scholar]
  33. Sylvestre P, Couture-Tosi E, Mock M. 2002; A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol45:169–178[CrossRef]
    [Google Scholar]
  34. Turnbull P. C. 1991; Anthrax vaccines: past, present and future. Vaccine9:533–539[CrossRef]
    [Google Scholar]
  35. Turnbull P. C. 2002; Introduction: anthrax history, disease and ecology. Anthrax271:1–19
    [Google Scholar]
  36. Uchida I, Hashimoto K, Terakado N. 1986; Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harboring or lacking 110 MDa and 60 MDa plasmids. J Gen Microbiol132:557–559
    [Google Scholar]
  37. Uchida I, Makino S, Sasakawa C, Yoshikawa M, Sugimoto C, Terakado N. 1993; Identification of a novel gene, dep , associated with depolymerization of the capsular polymer in Bacillus anthracis . Mol Microbiol9:487–496[CrossRef]
    [Google Scholar]
  38. Vodka M. H, Leppla S. H. 1983; Cloning of the protective antigen gene of Bacillus anthracis . Cell34:693–697[CrossRef]
    [Google Scholar]
  39. Watson J, Koya V, Leppla S. H, Daniell H. 2005; Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine22:4374–4384
    [Google Scholar]
  40. Welkos S. L, Friedlander A. M. 1988; Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog5:127–139[CrossRef]
    [Google Scholar]
  41. Williamson E. D, Hodgson I, Walker N. J.9 other authors 2005; Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun73:5978–5987[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.28788-0
Loading
/content/journal/micro/10.1099/mic.0.28788-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error